MedTrace Logo

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

NCT05704985 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-05-29

No results posted yet for this study

Summary

This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.

Conditions

Interventions

BIOLOGICAL

DK210 (EGFR)

Solution for SC administration

RADIATION

Radiation therapy

Short regimen radiation therapy (10 fractions or less)

BIOLOGICAL

Immune checkpoint blockers

IV administration of approved PD1 blocker

DRUG

Chemotherapy

Single agent or combination of not more than two

Sponsors & Collaborators

  • DEKA Biosciences

    lead INDUSTRY

Principal Investigators

  • Medical Officer · DEKA Biosciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-03
Primary Completion
2025-07-31
Completion
2025-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05704985 on ClinicalTrials.gov